GlassScriptPhysician profile
Robert W Price
NPI 1760480735
$6,626.11
in general payments reported to CMS, 2019-2025
23 companies · $883 in 2025
The $883 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $580 · 2020: $408 · 2021: $1,089 · 2022: $1,071 · 2023: $1,101 · 2024: $1,494 · 2025: $883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,458 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,458.11 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,521.31 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $1,243.71 | 2019-2025 | |
| Abbott Laboratories | $481.55 | 2019-2024 | Mitraclip, Cardiomems |
| Heartflow, INC. | $443.82 | 2023-2025 | Ffrct |
| Amgen INC. | $412.90 | 2019-2025 | Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $348.32 | 2021-2025 | |
| Boston Scientific Corporation | $257.95 | 2020-2025 | Watchman Access System, Watchman Flx |
| Pfizer INC. | $236.08 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $204.41 | 2020-2025 | Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.10 | 2021-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $186.33 | 2019-2025 | Camzyos, Eliquis |
| Kiniksa Pharmaceuticals International, Plc | $170.48 | 2024 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $151.14 | 2020-2025 | Lifevest |
| Edwards Lifesciences Corporation | $142.84 | 2021 | |
| Scpharmaceuticals INC. | $142.31 | 2023-2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $137.43 | 2024-2025 | Assure Wcd |
| Biotronik INC. | $111.76 | 2024 | Recross, Nhancer Rx, Orsiro Mission |
| Amarin Pharma, INC. | $90.87 | 2019 | |
| Cvrx, INC. | $53.30 | 2025 | Barostim Neo System |
| Astellas Pharma US INC | $35.69 | 2023 | Veozah |
| Vital Connect, INC | $30.26 | 2024 | Vitalpatch Rtm |
| Kiniksa Pharmaceuticals, LTD. | $19.78 | 2023 | Arcalyst |
| Irhythm Technologies, INC. | $15.77 | 2024 | Zio Xt Patch, Zio Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Price listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.